76939-46-3
76939-46-3
Chemical Structure
8-Bromo-cAMP sodium salt
Synonym(s): 8-Br-Camp sodium salt
- CAS No.: 76939-46-3
- Formula:C10H10BrN5NaO6P
- Molecular Weight:430.08
IUPAC Name: sodium (4aR,6R,7R,7aS)-6-(6-amino-8-bromo-9H-purin-9-yl)-7-hydroxytetrahydro-4H-furo[3,2-d][1,3,2]dioxaphosphinin-2-olate 2-oxide
InChIKey: DMRMZQATXPQOTP-GWTDSMLYSA-M
SMILES: BrC1=NC2=C(N=CN=C2N)N1[C@H](O[C@@](CO3)([H])[C@@]4([H])OP3(O[Na])=O)[C@@H]4O
Biological Activity: 8-Bromo-cAMP sodium (8-Br-Camp) sodium salt, a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP sodium salt has anti-proliferative and apoptotic effects against cancer cells[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
8-Bromo-cAMP sodium salt | 99.91% | 8-Bromo-cAMP sodium (8-Br-Camp) sodium salt, a cyclic AMP analog, is an activator of cyclic AMP-dependent protein kinase (PKA). 8-Bromo-cAMP sodium salt has anti-proliferative and apoptotic effects against cancer cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
8-Bromo-cAMP sodium salt (Standard) | ≥98% | 8-Bromo-cAMP sodium salt (Standard) is the analytical standard of 8-Bromo-cAMP sodium salt (HY-12306). This product is intended for research and analytical applications. 8-Bromo-cAMP sodium (8-Br-Camp) sodium salt, a cyclic AMP analog, is an activator of cyclic AMP-dependent protein Kinase (PKA). 8-Bromo-cAMP sodium salt has anti-proliferative and apoptotic effects against cancer cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wang Y, et al. A cyclic AMP analog, 8-Br-cAMP, enhances the induction of pluripotency in human fibroblast cells. Stem Cell Rev. 2011 Jun;7(2):331-41. [Content Brief]
- [2]. Wang HM, et al. Dual effects of 8-Br-cAMP on differentiation and apoptosis of human esophageal cancer cell line Eca-109. World J Gastroenterol. 2005 Nov 7;11(41):6538-42. [Content Brief]
